Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program-Reference-Cited by-同舟云学术

Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program

Published:2020-10-15 Issue:10 Volume:3 Page:e2020969
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Luo Jing¹,Feldman Robert¹,Rothenberger Scott D.¹,Hernandez Inmaculada²,Gellad Walid F.¹

Affiliation:

1. Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh, Pennsylvania

2. Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, University of Pittsburgh

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2771731/luo_2020_ld_200152_1602001041.69712.pdf

Reference6 articles.

1. Assessment of national coverage and out-of-pocket costs for sacubitril/valsartan under Medicare Part D.;DeJong;JAMA Cardiol,2019

2. Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in Medicare Part D, 2010 to 2019.;Dusetzina;JAMA,2019

3. Buprenorphine coverage in the Medicare Part D program for 2007 to 2018.;Hartung;JAMA,2019

4. Nationwide coverage and cost-sharing for PCSK9 inhibitors among Medicare Part D plans.;Kazi;JAMA Cardiol,2017

5. Impact of higher insulin prices on out-of-pocket costs in Medicare Part D.;Tseng;Diabetes Care,2020

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population‐Based Cohort Study;Movement Disorders;2024-08-27

2. Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study;Journal of General Internal Medicine;2024-07-31

3. Finerenone: Who should prescribe it for CKD? The physician associate’s perspective;Journal of Nephrology;2024-07-03

4. Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013–2021;BMC Cardiovascular Disorders;2024-05-30

5. Sociodemographic disparities in sodium‐glucose cotransporter‐2 inhibitor use among US kidney transplant recipients: An observational study of real‐world pharmacy records;Clinical Transplantation;2024-04